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We have carefully read the study titled “Population pharma-
cokinetics/pharmacodynamics of micafungin against Can-
dida species in obese, critically ill, and morbidly obese
critically ill patients” [1] and congratulate the authors for
such an interesting initiative.
The researchers conclude the lack of adequate mica-
fungin exposure with a 100 mg/24 h dose regardless of
the Candida species or the patient’s weight. Further,
micafungin exposure was adequate to cover Candida
albicans with a 150 mg/24 h dose for patients weighing
up to 115 kg and with a 200 mg/24 h dose for those sur-
passing this weight. The 200 mg/24 h dose covered Can-
dida glabrata for patients weighing up to 115 kg.
These results could correlate with, and also support
those that we previously obtained in the first study [2]
published on the pharmacokinetics (PK) of micafungin
in plasma and burn eschar tissue in critically ill patients
with severe burn injuries, which were compared with
the PK of micafungin in patients with intra-abdominal
infections [3]. In our study, 15 burn patients were com-
pared with ten patients with intra-abdominal infection;
all patients were treated with 100 to 150 mg/day of
micafungin.
We also observed that the standard dose of micafungin,
100 mg/day, achieves optimal PK/pharmacodynamics
(PD) targets in plasma for MIC values of 0.008 mg/L and
0.064 mg/L for non-parapsilosis Candida spp. and Can-
dida parapsilosis, respectively. By increasing the dose to
200 mg/day, the optimal PK/PD targets in plasma could
be achieved for MIC cutoff values that are twofold higher
(0.016 mg/L and 0.125 mg/L, respectively).
To these subpopulations of critically ill patients we must
add patients with sepsis and mechanical ventilation [4].
The authors recommended dose of 100 mg/day of mica-
fungin would be associated with a very low probability of
reaching the AUC0-24/MIC ratio in cases of infection with
C. albicans or C. glabrata with MIC ≥ 0.015 mg/L, as well
as in almost all cases of infection due to C. parapsilosis.
Finally, the conclusions presented above in relation to
the most recent PK studies of micafungin, performed in
different subpopulations of critically ill patients, would
provide us with significant evidence that we should con-
sider an increase in the standard dose (100 mg/day) for
the treatment of invasive candidiasis and that it would be
advisable, in our opinion, to propose PK/PD studies to pa-
tients in whom a lack of clinical or microbiological efficacy
due to a suboptimal dose of treatment is suspected.
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